Evotec SE (0IRF.IL)
| Previous close | 17.99 |
| Open | 17.69 |
| Bid | 17.27 x 0 |
| Ask | 18.16 x 0 |
| Day's range | 17.55 - 17.81 |
| 52-week range | 17.07 - 45.38 |
| Volume | |
| Avg. volume | 162,226 |
| Market cap | 3.139B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | 444.25 |
| EPS (TTM) | 0.04 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
EQS-News: Evotec SE / Key word(s): MiscellaneousJust – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program 20.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. JUST – EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABS EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES Hamburg, Germany, 20 September 2022:Evotec SE (Frankfurt
- EQS Group
Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
DGAP-News: Evotec SE / Key word(s): MiscellaneousEvotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU) 16.09.2022 / 15:00 CET/CESTThe issuer is solely responsible for the content of this announcement. J.POD® TOULOUSE, FRANCE (EU) BRINGS A DISRUPTIVE, FLEXIBLY SCALABLE BIOLOGICS MANUFACTURING TECHNOLOGY TO THE REGION THE MANUFACTURING FACILITY IS EXPECTED TO BE OPERATIONAL IN H2 2024 Hamburg, Germany, 16 September 2022:Evotec SE (Frankfurt Stock Exchange: EVT, M
- EQS Group
Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
DGAP-News: Evotec SE / Key word(s): MiscellaneousEvotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany 25.08.2022 / 07:31 CET/CESTThe issuer is solely responsible for the content of this announcement. EXPANSION OF CGMP DRUG SUBSTANCE MANUFACTURING PLATFORM WILL CREATE A CLEAR PATH TO THE MARKET FOR RARE DISEASES AND PRECISION THERAPEUTICS EVOTEC GAINS A FULLY OPERATIONAL EU GMP CERTIFIED FACILITY IN HALLE/WESTPHALIA ALONG WITH A HIGHLY SKIL
